Literature DB >> 25667781

Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer.

Uğur Selek1, Yasemin Bölükbaşı2, James W Welsh2, Erkan Topkan3.   

Abstract

Chemoradiotherapy is the current standard of care in patients with advanced inoperable stage IIIA or IIIB non-small cell lung cancer (NSCLC). Three-dimensional radiotherapy (3DCRT) has been a trusted method for a long time and has well-known drawbacks, most of which could be improved by Intensity Modulated Radiotherapy (IMRT). IMRT is not currently the standard treatment of locally advanced NSCLC, but almost all patients could benefit to a degree in organ at risk sparing, dose coverage conformality, or dose escalation. The most critical step for a radiation oncology department is to strictly evaluate its own technical and physical capabilities to determine the ability of IMRT to deliver an optimal treatment plan. This includes calculating the internal tumor motion (ideally 4DCT or equivalent techniques), treatment planning software with an up-to-date heterogeneity correction algorithm, and daily image guidance. It is crucial to optimise and individualise the therapeutic ratio for each patient during the decision of 3DCRT versus IMRT. The current literature rationalises the increasing use of IMRT, including 4D imaging plus PET/CT, and encourages the applicable knowledge-based and individualised dose escalation using advanced daily image-guided radiotherapy.

Entities:  

Keywords:  3-D conformal radiotherapy; intensity modulated radiotherapy; lung cancer

Year:  2014        PMID: 25667781      PMCID: PMC4318398          DOI: 10.5152/balkanmedj.2014.14529

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  58 in total

Review 1.  Intensity-modulated radiotherapy in the treatment of lung cancer.

Authors:  A Bezjak; R B Rumble; G Rodrigues; A Hope; P Warde
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-06-20       Impact factor: 4.126

2.  Dosimetric verification of the anisotropic analytical algorithm for radiotherapy treatment planning.

Authors:  Christopher M Bragg; John Conway
Journal:  Radiother Oncol       Date:  2006-11-27       Impact factor: 6.280

3.  Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer.

Authors:  Judith A Christian; James L Bedford; Steve Webb; Michael Brada
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-21       Impact factor: 7.038

4.  Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study.

Authors:  Simone Marnitz; Martin Stuschke; Jörg Bohsung; Anne Moys; Ines Reng; Reinhard Wurm; Volker Budach
Journal:  Strahlenther Onkol       Date:  2002-11       Impact factor: 3.621

5.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 6.  Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer.

Authors:  Joe Y Chang; H Helen Liu; Ritsuko Komaki
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

7.  Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy.

Authors:  Yvette Seppenwoolde; Hiroki Shirato; Kei Kitamura; Shinichi Shimizu; Marcel van Herk; Joos V Lebesque; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

8.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer.

Authors:  Ramesh Rengan; Kenneth E Rosenzweig; Ennapadam Venkatraman; Lawrence A Koutcher; Jana L Fox; Reena Nayak; Howard Amols; Ellen Yorke; Andrew Jackson; C Clifton Ling; Steven A Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

9.  A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Authors:  Shuanghu Yuan; Xindong Sun; Minghuan Li; Jinming Yu; Ruimei Ren; Yonghu Yu; Jianbin Li; Xiuqing Liu; Renben Wang; Baosheng Li; Li Kong; Yong Yin
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

10.  Hybrid IMRT for treatment of cancers of the lung and esophagus.

Authors:  Charles S Mayo; Marcia M Urie; Thomas J Fitzgerald; Linda Ding; Yuan Chyuan Lo; Madeleine Bogdanov
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-02-11       Impact factor: 7.038

View more
  5 in total

1.  Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry.

Authors:  Pierre Truntzer; Delphine Antoni; Nicola Santelmo; Catherine Schumacher; Pierre-Emmanuel Falcoz; Elisabeth Quoix; Gilbert Massard; Georges Noël
Journal:  Rep Pract Oncol Radiother       Date:  2016-05-05

Review 2.  Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?

Authors:  Marouan Benna; Jean-Baptiste Guy; Claire Bosacki; Omar Jmour; Majed Ben Mrad; Oleksandr Ogorodniitchouk; Saïd Soltani; Meiling Lan; Elisabeth Daguenet; Benoîte Mery; Sandrine Sotton; Nicolas Magné; Alexis Vallard
Journal:  Br J Radiol       Date:  2020-02-04       Impact factor: 3.039

3.  Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study.

Authors:  Xinglu Xu; Xin Ye; Gang Liu; Tingping Zhang
Journal:  Med Oncol       Date:  2015-08-05       Impact factor: 3.064

4.  A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Wenjuan Yang; Biao Zeng; Yanfang Qiu; Jianfeng Tan; Shilei Xu; Yilong Cai; Yujuan Zhou; Zhigang Liu; Junming Luo; Hui Wang
Journal:  Biomed Res Int       Date:  2017-05-28       Impact factor: 3.411

5.  Challenges of radical chemoradiation planning in Stage III non-small-cell lung cancer: Can volumetric modulated arc radiotherapy overcome an unfavourable location?

Authors:  Rakesh Kapoor; Namrata Das; Raviteja Miriyala; Ashwani Sood; Arun Oinam; Navneet Singh
Journal:  Phys Imaging Radiat Oncol       Date:  2020-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.